Study wrapper · #716
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.
Editor's note
This study pairs a small human association analysis with mouse and cell experiments on humanin and MOTS-c in atrial fibrillation (AF). In matched human samples (39 AF patients, 39 controls) plasma MOTS-c was lower in AF and tracked inversely with fibrosis and NT-proBNP. The causal work is preclinical: in an angiotensin-II mouse model and in rat cardiac cells, MOTS-c (and a humanin analogue) reduced AF inducibility and attenuated fibrosis and mitochondrial dysfunction. The human arm is cross-sectional and cannot establish direction; the interventional evidence is animal only. These are largely preclinical findings, and the authors call for larger cohorts and mechanistic follow-up. Read this as an early, internally consistent signal that MOTS-c is reduced in AF and modifies fibrosis pathways in animals, not as evidence for use in patients.
Plain-language abstract
Atrial fibrillation (AF) is a common irregular heart rhythm linked to scarring (fibrosis) and stressed mitochondria in the heart. Researchers studied two mitochondria-derived peptides, humanin and MOTS-c. Comparing 39 people with AF to 39 with normal rhythm, they found lower blood MOTS-c in AF, and lower levels went with more heart scarring. To test whether the peptides actually do something, they turned to mice and heart cells, using angiotensin II to trigger AF-like changes. Treating with MOTS-c (or a humanin version) made AF harder to induce and reduced scarring, inflammation, and mitochondrial damage; in isolated heart cells the peptides eased oxidative stress and calmed the scar-forming cells. Because the human part only shows an association at one point in time, it cannot prove MOTS-c protects the heart, and the treatment benefits were seen only in animals and cells. The authors say bigger human studies are needed. This is an early but consistent hint worth watching.